Alternative ETV6-JAK2 fusions have been identified in both ALL and atypical chronic myelogenous leukemia (CML), that lead to constitutive activation of the JAK2 tyrosine kinase and downstream pathways [76,77]. Here, JAK2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.